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Objectives. We sought o determine an anticoagulation protocol 
for use during cardiac catheterization in children. 
Background. There are few data to indicate which dose of 
heparin represents adequate anticoagulation or how best to 
monitor its efficacy. In this study, adequate anticoagulation was 
defined as the amount of heparin needed to prevent a significant 
increase in serum fibrinopeptide A, a sensitive marker for throm- 
bin activity. The degree of heparinization was estimated by the 
activated clotting time. 
Methods. Thirty-six children (1 month to 19.5 years old) with 
congenital heart disease underwent diagnostic ardiac catheter- 
ization; 13 of these 36 patients had an additional interventional 
procedure. Sheaths and catheters were flushed with heparinized 
saline (1 IU/ml); during the procedure, 33 of the 36 patients 
received either a 50- or a 100-IU/kg heparin bolus. Paired 
fibrinopeptide A and activated clotting time samples were ob- 
tained throughout each procedure. 
Results. Increasing the activated clotting time with heparin 
resulted in a dose-related decrease in fibrinopeptide A levels. A 
single heparin bolus of either 50 or 100 IU/kg elevated the 
activated clotting time above baseline level (209 - 52 s after 50 
IU/kg, 270 -+ 57 s after 100 IU/kg vs. 133 -+ 20 s at baseline [p < 
0.0001]) and reduced fibrinopeptide A levels below baseline (7.9 -+ 
14 ng/ml after 50 IU/kg, 4.8 -+ 3.7 ng/ml after 100 IU/kg vs. 38 _ 
59 ng/ml at baseline [p < 0.0001]). Heparin flush alone did not 
increase the activated clotting time above baseline and failed to 
suppress an increase in fibrinopeptide A levels. There were no 
differences in activated clotting time and fibrinopeptide A values 
between patients undergoing diagnostic or interventional proce- 
dures. 
Conclusions. Administration of a heparin bolus to maintain an 
activated clotting time >200 s prevented a significant increase in 
thrombin activity. Heparin flush alone did not provide adequate 
anticoagulation. Patients undergoing an interventional procedure 
did not require more heparin than that needed for a diagnostic 
procedure. 
(J Am Coil Cardiol 1995;25:725-9) 
Systemic anticoagulation with heparin reduces the risk of 
thromboembolic complications during cardiac catheterization 
in both adults and children (1-3). However, there is little 
consensus on what constitutes adequate anticoagulation, how 
much heparin is needed to achieve that level of anticoagulation 
and how best to monitor its effectiveness. 
Fibrinopeptide A is a 16-amino acid peptide cleaved from 
fibrinogen by thrombin with a half-life of 3 to 5 rain in serum. 
Increased serum fibrinopeptide A levels have proved to be a 
sensitive marker for thrombin activity and of subsequent 
intravascular fibrin generation and thrombosis (4-6). Hepa- 
rin's efficacy as an anticoagulant agent results primarily from 
its ability to inhibit thrombin. Adequate anticoagulation can 
therefore be defined as the amount of heparin needed to 
prevent a significant increase in plasma fibrinopeptide A 
concentration (4,6,7). The degree of heparinization is conve- 
niently estimated in the catheterization suite by the activated 
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clotting time. Using these definitions, we sought o determine 
a heparin protocol that provides adequate anticoagulation 
during cardiac catheterization i  children. 
Methods  
Patients. The study group consisted of 36 patients with 
congenital heart disease who underwent cardiac catheteriza- 
tion between May and August 1993. The mean age was 5.7 
years (range 1 month to 19.5 years). Five of the children had 
cyanotic heart disease with arterial oxygen saturation <85%. 
Procedures. A diagnostic, hemodynamic catheterization r
an electrophysiologic study was performed in all 36 patients; 13 
patients had an additional interventional procedure (endom- 
yocardial biopsy in 4, balloon dilation in 5, stent placement in 
3 and coil embolization in 1). Vascular access was obtained 
percutaneously. Distal leg pulses were evaluated before and 
immediately after each procedure. The study was approved by 
the human studies committee of our institution. 
Study protocol. To assess the effect of variation in the 
heparinization protocol, patients were treated as follows: no 
heparin bolus was given to 3 patients without intracardiac 
shunting who underwent right heart catheterization only, a 
heparin bolus of 50 IU/kg body weight was administered to 15 
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patients and a bolus of 100 lU/kg was administered to 18 
patients. At the catheterizing physician's discretion, the timing 
of the heparin bolus ranged from immediately after to 112 rain 
after sheath placement. All patients, both before and after a 
heparin bolus, had sheaths and catheters outinely flushed with 
heparinized saline (1 IU/ml). 
A baseline sample for measurement of activated clotting 
time was obtained immediately after insertion of a saline- 
flushed sheath at the start of each procedure. A baseline 
sample for measurement of fibrinopeptide A was then ob- 
tained through the sheath after a single heparin flush. Paired 
fibrinopeptide A and activated clotting time samples were then 
collected approximately every 30 rain. Given the hepariniza- 
tion protocol described above, samples were collected under 
three conditions: 1) heparin flush only (24 samples from 19 
patients), 2) after a 50-IU/kg heparin bolus (26 samples from 
15 patients), or 3) after a 100-IU/kg heparin bolus (34 samples 
from 18 patients), The heparin flush only group includes 
samples from the 3 patients who received no heparin bolus in 
addition to samples obtained before a heparin bolus in 16 
other patients. 
The baseline fibrinopeptide A sample and all subsequent 
sample collections for both fibrinopeptide A and activated 
clotting time were drawn from a sheath or catheter, venous or 
arterial, in the following manner: 1) The sheath or catheter was 
flushed with 3 to 4 ml of heparinized saline (1 IU/ml); 2) an 
appropriate void volume of blood (3 to 4 ml) was removed; and 
3) the sample was obtained. 
To assess the effect of a single heparinized flush on fibrino- 
peptide A levels, fibrinopeptide A was initially measured 
immediately after placement ofa saline only-flushed sheath in 
21 of the 36 patients. A second fibrinopeptide A measurement 
was then obtained after the sheath was flushed with a single 
heparinized flush. 
To estimate a normal circulating fibrinopeptide A level in 
children with congenital heart disease, blood samples were 
obtained in seven additional patients (mean age 9 years [range 
14 months to 15 years]). In these patients, immediately after 
placement of a venous sheath, a 6F heparin-bonded catheter 
(Cook Inc.) was placed into the right atrium without a guide 
wire (8). Paired fibrinopeptide A samples were obtained in the 
manner described. 
Blood for fibrinopeptide A (0.95 ml of blood/sample) 
measurements was collected in heparinized tuberculin syringes 
and immediately placed in precooled vials containing fibrin- 
opeptide A anticoagulant. Quantitative determination f fi- 
brinopeptide A was performed by using the radioimmunoassay 
method of RIA-mat fibrinopeptide A by BYK-Sangtec Diag- 
nostica (Dietzenbach, Germany). Blood for activated clotting 
time measurement (0.4 ml/sample) was collected in nonhepa- 
rinized tuberculin syringes, placed immediately in Hemochron 
P214/P215 tubes and run as paired samples on a dual- 
chambered Hemochron 801 activated clotting time monitor 
(International Technidyne). 
Statistics. Data are expressed as mean value _+ 1 SD. 
Statistical comparisons were made by using the Kruskal-Wallis 
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Figure 1. Activated clotting time (ACT) values obtained at baseline 
and over a 2-h catheterization period under three heparin conditions: 
heparin flush only (24 samples from 19 patients); a 50-1U/kg body 
weight heparin bolus (26 samples from 15 patients); ora 100-IU/kg 
heparin bolus (34 samples from 18 patients). *p< 0.0001, compared 
with baseline or heparin flush only. **p < 0.0001, compared with after 
a 50-IU/kg heparin bolus. Data represent mean value + SD. 
test and the Wilcoxon rank sum test. A two-tailed p value 
<0.05 was considered significant. In cases of multiple compar- 
isons a Bonferroni correction was applied. 
Resu l ts  
Activated clotting time. Figure 1 compares the activated 
clotting time obtained at baseline with that obtained under the 
three heparin conditions (heparin flush only and after a single 
50-IU/kg or a 100-IU/kg heparin bolus) averaged over a 2-h 
time period. Heparin flush alone did not increase the activated 
clotting time above baseline (133 _+ 19 vs. 133 + 20 s, p = 
0.84). However, a 50- or 100-IU/kg heparin bolus did signifi- 
cantly elevate the activated clotting time (209 _+ 52 and 270 _+ 
57 s, respectively) above the value obtained at baseline or with 
heparin flush only (p < 0.0001). A 100-IU/kg heparin bolus 
significantly increased the activated clotting time more than a 
50-IU/kg bolus (p < 0.0001). Figure 2 shows the change in the 
activated clotting time over 2 h after a single 100-IU/kg bolus 
of heparin. 
Fibrinopeptide A levels. In 35 of the 36 patients, a baseline 
fibrinopeptide A level measured after a single heparin flush 
was 38 _+ 59 ng/ml. In 21 of these 36 patients, fibrinopeptide A 
levels were obtained before the heparin flush. These fibrin- 
JACC Vol. 25, No. 3 GRADY ET AL  727 
March 1, 1995:725-9 HEPARIN USE IN PEDIATRIC  CATHETERIZAT ION 
500 
8 
I-- 
O ,< 
400 
300 
200 
o 
o 
o 
o 
o 
g 
o 
o 
o o o o o 
%o o g 
o o o o 
o 
q9 o 
0 0 
100 
o Jo 6'0 9'o ,;o 
TIME (minutes) 
Figure 2. Activated clotting time (ACT) values (34 measurements in
18 patients) obtained over a 2-h time period after a single 100-IU/kg 
bolus of heparin. 
opeptide A levels, measured from samples drawn through a 
sheath flushed with saline only, were markedly elevated (140 ± 
122 ng/ml). After a single heparin flush, the fibrinopeptide A 
levels in these 21 patients were reduced significantly to 54 _+ 
73 ng/ml (p = 0.003). 
Figure 3. Fibrinopeptide A (FPA) values obtained at baseline and 
over a 2-b catheterization period under the three heparin conditions. 
*p < 0.0001, compared with baseline or heparin flush only. Data 
represent mean value + SD. Number of samples and patients as in 
Figure 1. 
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Table 1. Paired Fibrinopeptide A Samples From Seven 
Control Patients 
Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 Pt 7 
FPA sample 1 (ng/ml) 8.4 2.0 5.5 5.0 25.0 6.3 2.1 
FPA sample 2 (ng/ml) 8.3 2.1 6.3 4.5 21.0 8.3 2.1 
FPA = fibrinopeptide A; Pt = patient. 
Figure 3 shows the corresponding fibrinopeptide A values 
from samples collected over the same 2-h time period used to 
obtain the activated clotting time values shown in Figure 1. 
With heparin flush only, the fibrinopeptide A level (22 _+ 32 
ng/ml) was not different from that at baseline (38 _+ 59 ng/ml) 
(p = 0.07). However, a 50- or 100-IU/kg heparin bolus lowered 
the fibrinopeptide A level below the value obtained at baseline 
or with heparin flush alone (7.9 _+ 14 ng/ml after a 50-IU/kg 
bolus, 4.8 _+ 3.7 ng/ml after a 100-IU/kg bolus [p < 0.0001 vs. 
baseline or heparin flush only]). Unlike the activated clotting 
time, the fibrinopeptide A levels collected after a 50- or 
100-IU/kg bolus were not different from each other (p = 0.55). 
The fibrinopeptide A level obtained in seven patients with 
the use of heparin-bonded catheters was 7.6 ± 7.1 ng/ml 
(median 5.9 ng/ml) (Table 1). Fibrinopeptide A levels mea- 
sured after a 50- or a 100-IU/kg bolus of heparin were similar 
to those obtained through the heparin-bonded catheters (p = 
0.20). However, fibrinopeptide A levels obtained using heparin 
flush alone were higher than those obtained through heparin- 
bonded catheters; this difference was of marginal statistical 
significance (p = 0.05). 
The results of all paired fibrinopeptide A/activated clotting 
time samples (135 samples), collected from all 36 patients are 
shown in Figure 4. When the activated clotting time was 
>200 s, the mean fibrinopeptide A level was 4.5 + 3.3 ng/ml. 
Figure 4. Relation between all paired fibrinopeptide A (FPA) and 
activated clotting time (ACT) samples collected before and after a 
heparin bolus (135 samples from 36 patients). 
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Table 2. Measured Activated Clotting Time and Fibrinopeptide A 
Values for Interventional and Diagnostic Procedures 
Heparin Flush After 50-lU/kg After 100-lU/kg 
Only Heparin Bolus Heparin Bolus 
FPA FPA FPA 
ACT (s) (ng/ml) ACT (s) (ng/ml) ACT (s) (ng/ml) 
130_+11 36_+67 192_+61 9.2_+14 258+44 5.1_+4.4 Interventional 
procedures 
(n : 13) 
Diagnostic 
procedures 
(n = 23) 
136_+23 28_+32 213+49 7.6_+15 280_+66 4.7_+3.1 
All values given are the mean value _+ SD. There was no significant 
difference between the measured activating clotting time (ACT) and fibrinopep- 
tide A (FPA) values of patients undergoing interventional versus diagnostic 
procedures. 
Diagnostic versus interventional procedures. There were 
no significant differences in activated clotting time or fibrino- 
peptide A values between patients undergoing diagnostic 
versus interventional procedures (Table 2). 
Complications. None of the 36 patients experienced a
pulse loss after the procedure. Two patients had mildly dimin- 
ished distal pulses after the catheterization; neither was treated 
with a heparin infusion. 
Discuss ion  
Background. Systemic anticoagulation has been shown to 
reduce thromboembolic complications during cardiac atheter- 
ization in both adults and children (1-3). In children, before 
the use of systemic anticoagulation, the incidence of femoral 
artery thrombosis ranged from 4% to 40% (2,3,9). After 
systemic heparinization with heparin was introduced in the 
early 1970s, the incidence of vascular complications inchildren 
decreased to 0.8% to 8% (2,3,10-13). However, with the 
relatively recent advent of interventional procedures in pedi- 
atric patients, with longer procedure times and larger sheaths 
and catheters, the incidence of thromboembolic complications 
has risen. Investigators (10-14) report vascular complication 
rates in interventional procedures three to six times higher 
than those of diagnostic procedures, despite systemic hepa- 
rinization. The risk is especially high in infants. The rate of 
occurrence of venous thrombosis after cardiac atheterization 
has been estimated to be as high as 4% to 7% (15,16). As more 
children with complex heart disease survive longer and require 
multiple catheterizations, the issue of thrombosed vessels, both 
arterial and venous, becomes increasingly important and can 
ultimately determine a child's future therapeutic options. 
Despite these concerns and the widespread use of heparin 
for systemic anticoagulation during cardiac catheterization, 
there is little information on what dose of heparin constitutes 
adequate anticoagulation a d how best to monitor its efficacy. 
The majority of protocols reported to date (2,3,10-14) appear 
to be empirically derived. These protocols, assuming arterial 
catheterization, give a fixed heparin bolus of 50 to 150 IU/kg at 
the start of the procedure with little subsequent discussion as 
to whether the bolus was effective and if and when should more 
heparin be given. Whether to administer heparin in patients 
undergoing right heart catheterization alone (without an oblig- 
atory right to left shunt) has not been discussed. 
The pharmacokinetics and clinical effect of heparin vary 
significantly from patient o patient (17). This variability can be 
especially pronounced in children, depending on their physical 
maturity (18). Therefore, use of a fixeddose heparin protocol, 
without monitoring of efficacy, can result in significant over- 
coagulation or undercoagulation. Our study examined what 
constitutes an adequate l vel of anticoagulation a d how much 
heparin is needed to achieve that level during pediatric ath- 
eterizations. 
Fibrinopeptide A is the first peptide to be cleaved from 
fibrinogen by thrombin in the coagulation process. The result- 
ing fibrin monomer polymerizes into a fibrin clot. The half-life 
of fibrinopeptide A in the circulation is 3 to 5 min. Fibrinopep- 
tide A is therefore a sensitive indicator of intravascular fibrin 
formation, and an increase in plasma fibrinopeptide A has 
been correlated with clinical thrombotic events (4-7). Because 
heparin acts to prevent thrombin activity, we defined adequate 
anticoagulation in our study as the amount of heparin needed 
to prevent a significant rise in serum fibrinopeptide A levels. 
The degree of heparinization was determined by the activated 
clotting time. 
Current study. Heparin protocol and thrombin activity. We 
found that increasing the activated clotting time with heparin 
resulted in a dose-related ecrease in thrombin activity as 
measured by fibrinopeptide A concentrations (Fig. 4). Use of 
either a 50- or a 100-IU/kg bolus of heparin kept the activated 
clotting time >200 s and suppressed any significant increase in 
fibrinopeptide A for 2 h. The use of heparin flush (1 IU/ml) 
alone resulted in increased thrombin activity and significantly 
elevated fibrinopeptide A levels. Patients undergoing an inter- 
ventional procedure did not have significantly higher fibrin- 
opeptide A levels and did not require more heparin than that 
required for a diagnostic procedure. 
Role of intravascular sheaths in thrombin activity. The sig- 
nificant thrombotic potential of the intravascular sheaths is 
suggested by our observation that the fibrinopeptide A level 
obtained immediately after placement of a saline solution- 
flushed sheath was quite high at 140 _+ 122 ng/ml. After a single 
flush of the sheath with only 3 to 4 ml of heparinized saline 
solution, the fibrinopeptide A level decreased substantially to 
54 _+ 73 ng/ml. We believe that these very high fibrinopeptide 
A levels (>40 ng/ml) do not represent systemic thrombin 
activity; rather, they reflect local activation secondary either to 
thrombus on the sheath or to the procoagulant effect of 
drawing blood through the sheath. 
Sustained heparin effect without systemic heparinization. In 
Figure 4 there are many points where the activated clotting 
time is considerably <200 s yet the fibrinopeptide A also 
remains low (<10 ng/ml). Many of these points represent 
samples collected later in a procedure after multiple heparin 
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flushes or a heparin bolus, or both, were given (data not 
shown). These data suggest that heparin has a sustained effect 
against fibrin formation despite the absence of systemic hepa- 
rinization. This protection most likely reflects the local accu- 
mulation of heparin on or around the sheaths, which are 
present throughout every procedure. 
Limitations of the study. Although our study group in- 
cluded children over a wide age range, both with and without 
cyanosis, the group was not large enough to permit comparison 
of the effect of cyanosis and age on fibrinopeptide A produc- 
tion and heparin response. In addition, our activated clotting 
time values were obtained by using the Hemochron monitor 
and may not be directly comparable tothose obtained with the 
HemoTec activated clotting time monitor (HemoTec, Inc.) 
(19). 
Conclusions. On the basis of these fndings, our current 
clinical practice is to give every child a 50- or a 100-IU/kg bolus 
of heparin at the beginning of every procedure; this includes 
patients undergoing an uncomplicated right heart catheteriza- 
tion. There was no statistical difference between fibrinopeptide 
A levels obtained after a 50- or a 100-IU/kg bolus. However, a
100-IU/kg bolus was more consistent in raising the activated 
clotting time to >200 s, resulting in a trend toward lower 
fibrinopeptide A levels. We therefore give a 100-IU/kg bolus of 
heparin to patients with an increased risk of thromboembolic 
complications, such as infants weighing <5 kg in whom an 
arterial sheath is used, patients undergoing selective coronary 
angiography and patients in whom a prosthetic aortopulmo- 
nary shunt is crossed with a wire or catheter. The initial bolus 
is given to achieve an activated clotting time >200 s, and the 
bolus is repeated if necessary. We monitor the activated 
clotting time approximately every 1 to 2 h, giving additional 
heparin as needed to keep the activated clotting time >200 s. 
Further investigation may result in variation of this protocol 
for specific subgroups of patients. 
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